Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy

Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy

The Triple-Negative Breast Cancer subtype (TNBC) is particularly aggressive and heterogeneous. Thus, Poly-ADP-Ribose Polymerase inhibitors were developed to improve the prognosis of patients and treatment protocols are still being evaluated. In this context, we modelized the efficacy of Olaparib (i....

Full description

Bibliographic Details
Main Authors: Clémence Dubois, Fanny Martin, Chervin Hassel, Florian Magnier, Pierre Daumar, Corinne Aubel, Sylvie Guerder, Emmanuelle Mounetou, Frédérique Penault-Lorca, Mahchid Bamdad
Format: Article
Language:English
Published: MDPI AG 2019-12-01
Series:Journal of Clinical Medicine
Subjects:
triple-negative breast cancer
sum1315
mda-mb-231
parpi olaparib
fractioned radiotherapy
co-treatment
the three-dimensional cell culture
spheroid
transcriptomic analysis
Online Access:https://www.mdpi.com/2077-0383/9/1/64

Internet

https://www.mdpi.com/2077-0383/9/1/64

Similar Items